技术领域technical field
本发明涉及一种评价疾病诊断状况的检测技术，尤其涉及一种评价结核病治疗的细胞因子，以及检测这些细胞因子的试剂盒。The present invention relates to a detection technique for evaluating disease diagnosis status, in particular to a cytokine for evaluating treatment of tuberculosis and a kit for detecting these cytokines.
背景技术Background technique
结核病(Tuberculosis，TB)是由结核分枝杆菌(Mycobacterium tuberculosis，MTB)引起的一种慢性传染病，据2014年WHO的统计，我国新发肺结核人数93万人，在22个结核病高负担国家中仅次于印度和印度尼西亚居第三位，结核病是我国单因素致死率最高的慢性传染性疾病。流行病学显示全世界约有1/3人口为结核分枝杆菌携带者，其中约10％的携带者可发展为活动性结核病[2]。随着多重耐药结核(multidrug resistancetuberculosiscle bacillus，MDR-TB)的流行及人类免疫缺陷病毒(Human immunedeficiency vinus，HIV)感染的增多，让结核分枝杆菌的感染更加难以控制，所以实现结核病一级预防的前提就是提高结核病的诊断效能。Tuberculosis (TB) is a chronic infectious disease caused by Mycobacterium tuberculosis (MTB). According to the statistics of WHO in 2014, there were 930,000 new cases of tuberculosis in my country, among the 22 countries with a high burden of tuberculosis. Ranked third after India and Indonesia, tuberculosis is the chronic infectious disease with the highest single-factor fatality rate in my country. Epidemiology shows that about 1/3 of the world's population is a carrier of Mycobacterium tuberculosis, and about 10% of the carriers can develop active tuberculosis [2]. With the prevalence of multidrug resistance tuberculosis cle bacillus (MDR-TB) and the increase of human immunodeficiency virus (Human immunodeficiency vinus, HIV) infection, the infection of Mycobacterium tuberculosis is more difficult to control, so the primary prevention of tuberculosis is realized The premise is to improve the diagnostic efficiency of tuberculosis.
现有的结核病实验室诊断方法主要分为三类：细菌学方法、分子生物学方法以及免疫学方法。细菌学诊断方法主要有涂片染色显微镜检和分枝杆菌分离培养，是结核病实验室诊断的常用技术，但是由于涂片镜检的低检出率和分离培养周期较长，造成了漏检及延误治疗，增加疾病传播的机会；分子生物学检测主要基于体外核酸扩增技术，其敏感性增高的同时易出现假阳性，而且难以获得含有分枝杆菌DNA的合适样本因而限制了其应用；免疫学诊断方法包括结核菌素试验、结核抗原以及结核抗体检测。结核分枝杆菌是典型的细胞内寄生菌，人体免疫系统抗击结核分枝杆菌的主要方式是细胞免疫。随着细胞和分子免疫学研究的进展，发现了一些与结核病免疫及发病有关的细胞因子，在机体感染结核分枝杆菌的过程中，活化的免疫细胞会分泌大量的细胞因子参与机体的免疫反应，在抗结核治疗的过程中，其水平也会产生相应的改变，所以改变的细胞因子水平不仅可以成为结核病诊断的标志物，甚至可以对结核病治疗过程进行监测，指导临床用药。The existing laboratory diagnostic methods for tuberculosis are mainly divided into three categories: bacteriological methods, molecular biological methods and immunological methods. Bacteriological diagnostic methods mainly include smear staining microscopy and mycobacterial isolation and culture, which are commonly used techniques for laboratory diagnosis of tuberculosis. Delay in treatment increases the chance of disease transmission; molecular biology testing is mainly based on in vitro nucleic acid amplification technology, which has increased sensitivity and is prone to false positives, and it is difficult to obtain suitable samples containing mycobacterial DNA, thus limiting its application; Clinical diagnostic methods include tuberculin test, tuberculosis antigen and tuberculosis antibody detection. Mycobacterium tuberculosis is a typical intracellular parasite, and the main way for the human immune system to fight against Mycobacterium tuberculosis is cellular immunity. With the progress of cellular and molecular immunology research, some cytokines related to tuberculosis immunity and pathogenesis have been discovered. During the process of body infection with Mycobacterium tuberculosis, activated immune cells will secrete a large number of cytokines to participate in the body's immune response , in the process of anti-tuberculosis treatment, its level will also change accordingly, so the changed cytokine level can not only become a marker for tuberculosis diagnosis, but can even monitor the process of tuberculosis treatment and guide clinical medication.
IFN-γ作为一种异型糖蛋白，通过与相应的受体结合来调节机体免疫系统，在结核病患者体内可以反映机体抗结核的免疫状态，并且与结核菌的载菌量相关，结核分枝杆菌感染机体以后，T细胞会识别并产生高水平的IFN-γ来进行抵抗，所以目前被广泛用于结核病的诊断。例如已有针对γ-干扰素(IFN-γ)释放试验(interferon-gamma releaseassay，IGRAs)的商品化试剂盒T.SPOT.TB和QuantiFERON-TB Gold In-Tube (QFT-IT)。但是，IFN-γ作为现有商品化结核分枝杆菌感染细胞免疫检测试剂中唯一的检测靶标，其敏感性和特异性并不能满足临床的要求，其原因可能一方面在于IFN-γ的检测性能不够高，部分研究表明其诊断结核病的准确性较低。另一方面，对于结核病这样异质性高的疾病而言，单一靶标的检测性能具有一定的局限性，国内外学者也在寻找更好的用于诊断结核病的生物标志物，探索联合多种细胞因子进行诊断的可能性。As a heterogeneous glycoprotein, IFN-γ regulates the body's immune system by binding to the corresponding receptors. In tuberculosis patients, it can reflect the body's anti-tuberculosis immune status and is related to the bacterial load of tuberculosis. Mycobacterium tuberculosis After infecting the body, T cells will recognize and produce high levels of IFN-γ for resistance, so it is currently widely used in the diagnosis of tuberculosis. For example, there are commercial kits T.SPOT.TB and QuantiFERON-TB Gold In-Tube (QFT-IT) for γ-interferon (IFN-γ) release assays (interferon-gamma release assays, IGRAs). However, as the only detection target of IFN-γ in the existing commercial Mycobacterium tuberculosis infection cell immunoassay reagents, its sensitivity and specificity cannot meet the clinical requirements. The reason may be the detection performance of IFN-γ on the one hand. It is not high enough, and some studies have shown that its accuracy in diagnosing tuberculosis is low. On the other hand, for a disease with high heterogeneity such as tuberculosis, the detection performance of a single target has certain limitations. factor for the possibility of diagnosis.
中国发明专利申请201210559258.6公开了一种单核细胞趋化蛋白2作为结核性胸水检测的标志物，MCP-2/CCL8蛋白作为鉴别诊断结核性胸水的标志物。Chinese invention patent application 201210559258.6 discloses a monocyte chemoattractant protein 2 as a marker for the detection of tuberculous pleural effusion, and MCP-2/CCL8 protein as a marker for differential diagnosis of tuberculous pleural effusion.
中国发明专利申请201510317166.0公开了一种基于结核特异性IL-31检测的诊断结核分枝杆菌感染的试剂盒，包括IL-31捕获抗体和检测抗体、结核特异性抗原多肽、稀释液、标准品、显色液、终止液、缓冲液、固体载体和封板膜等。Chinese invention patent application 201510317166.0 discloses a kit for diagnosing Mycobacterium tuberculosis infection based on tuberculosis-specific IL-31 detection, including IL-31 capture antibody and detection antibody, tuberculosis-specific antigen polypeptide, diluent, standard, Chromogenic solution, stop solution, buffer, solid support and sealing film, etc.
中国发明专利申请201410182316.7公开了一种活动性肺结核的免疫诊断试剂盒，该试剂盒能特异性识别细胞因子I-309、MIG、IL-8中至少一个，也可对所识别的细胞因子进行定量分析，也可以联合对结核分枝杆菌抗原38-KDa、32-KDa、14-16-KDa和Ag85B的特异性IgG抗体进行特异性识别。Chinese invention patent application 201410182316.7 discloses an immunodiagnostic kit for active pulmonary tuberculosis, which can specifically recognize at least one of cytokines I-309, MIG, and IL-8, and can also quantify the identified cytokines Analysis can also be combined with specific recognition of specific IgG antibodies to Mycobacterium tuberculosis antigens 38-KDa, 32-KDa, 14-16-KDa and Ag85B.
中国发明专利申请201410182365.0公开了一种结核分枝杆菌潜伏感染的诊断试剂盒，试剂盒能特异性识别细胞因子Eotaxin-2、MIG、Eotaxin、MCSF或IL-12p70中至少一个，并能对所识别的细胞因子进行定量分析，还可以特异性识别抗原38-KDa、32-KDa、14-16-KDa和Ag85B的特异性IgG抗体。Chinese invention patent application 201410182365.0 discloses a diagnostic kit for latent infection of Mycobacterium tuberculosis, the kit can specifically recognize at least one of the cytokines Eotaxin-2, MIG, Eotaxin, MCSF or IL-12p70, and can identify Quantitative analysis of cytokines can also specifically recognize the specific IgG antibodies of antigens 38-KDa, 32-KDa, 14-16-KDa and Ag85B.
发明内容Contents of the invention
本发明的一个目的在于提供一种RANTES细胞因子作为标记物在制备诊断或监测结核病的试剂盒中的应用。An object of the present invention is to provide an application of a RANTES cytokine as a marker in the preparation of a kit for diagnosing or monitoring tuberculosis.
本发明的另一个目的在于提供一种RANTES细胞因子为标记物在制备诊断或监测结核病治疗效果的试剂盒中的应用。Another object of the present invention is to provide an application of a RANTES cytokine as a marker in the preparation of a kit for diagnosing or monitoring the treatment effect of tuberculosis.
本发明的再一个目的在于提供一种RANTES细胞因子为标记物在结核病疗效预测试剂盒中的应用。Another object of the present invention is to provide an application of a RANTES cytokine as a marker in a tuberculosis curative effect prediction kit.
本发明的又一个目的在于提供一种RANTES细胞因子为标记物在结核病治疗早期疗效预测试剂盒中的应用。Another object of the present invention is to provide an application of RANTES cytokine as a marker in a kit for predicting the early curative effect of tuberculosis treatment.
细胞因子(cytokine)是免疫原、丝裂原或其他刺激剂诱导多种细胞产生的低分子量可溶性蛋白质，具有调节固有免疫和适应性免疫、血细胞生成、细胞生长以及损伤组织修复等多种功能。细胞因子可被分为白细胞介素、干扰素、肿瘤坏死因子超家族、集落刺激因子、趋化因子和生长因子等。Cytokines are low-molecular-weight soluble proteins produced by various cells induced by immunogens, mitogens, or other stimulants, and have multiple functions such as regulating innate and adaptive immunity, hematopoiesis, cell growth, and repair of damaged tissues. Cytokines can be divided into interleukins, interferons, tumor necrosis factor superfamily, colony-stimulating factors, chemokines and growth factors, etc.
炎症蛋白10(IP-10)、嗜酸性粒细胞趋化因子(Eotaxin)和正常T细胞表达和分泌因子(RANTES)均属于趋化因子家族的细胞因子。Inflammatory protein 10 (IP-10), eosinophil chemokine (Eotaxin) and normal T cell expressed and secreted factors (RANTES) are cytokines belonging to the chemokine family.
白细胞介素(IL)主要由淋巴细胞产生，包括T淋巴细胞、B淋巴细胞和NK细胞等。IL-6属于一种白细胞介素。Interleukin (IL) is mainly produced by lymphocytes, including T lymphocytes, B lymphocytes and NK cells. IL-6 is a type of interleukin.
IFN-γ属于干扰素之一种，根据干扰素产生的来源和结构不同，可分为IFN-α、IFN-β和IFN-γ，他们分别由白细胞、成纤维细胞和活化T细胞所产生。各种不同的IFN生物学活性基本相同，具有抗病毒、抗肿瘤和免疫调节等作用。IFN-γ belongs to one type of interferon. According to the source and structure of interferon, it can be divided into IFN-α, IFN-β and IFN-γ, which are produced by leukocytes, fibroblasts and activated T cells respectively. The biological activities of various IFNs are basically the same, and they have antiviral, antitumor and immune regulation effects.
细胞因子RANTES作为标记物在制备诊断或监测结核病的试剂盒中的应用。The application of the cytokine RANTES as a marker in the preparation of a kit for diagnosing or monitoring tuberculosis.
细胞因子RANTES作为标记物在制备诊断或监测结核病治疗效果的试剂盒中的应用。The application of the cytokine RANTES as a marker in the preparation of a kit for diagnosing or monitoring the treatment effect of tuberculosis.
细胞因子RANTES作为标记物在结核病疗效预测试剂盒中的应用。The application of cytokine RANTES as a marker in the tuberculosis curative effect prediction kit.
细胞因子RANTES作为标记物在在结核病治疗早期疗效预测试剂盒中的应用。The application of cytokine RANTES as a marker in a kit for predicting the early therapeutic effect of tuberculosis treatment.
细胞因子Eotaxin和细胞因子IP-10之一种或几种与细胞因子RANTES组合作为标记物在制备诊断或监测结核病的试剂盒中的应用。One or more of the cytokine Eotaxin and the cytokine IP-10 combined with the cytokine RANTES is used as a marker in the preparation of a kit for diagnosing or monitoring tuberculosis.
细胞因子Eotaxin和细胞因子IP-10之一种或几种与细胞因子RANTES组合作为标记物在制备诊断或监测结核病治疗效果的试剂盒中的应用。One or more of the cytokine Eotaxin and the cytokine IP-10 combined with the cytokine RANTES is used as a marker in the preparation of a kit for diagnosing or monitoring the treatment effect of tuberculosis.
一种试剂盒，以细胞因子RANTES为标记物。A kit uses the cytokine RANTES as a marker.
试剂盒还以细胞因子Eotaxin和细胞因子IP-10之一种或几种为标记物。The kit also uses one or more of the cytokine Eotaxin and the cytokine IP-10 as markers.
试剂盒还包括检测细胞因子RANTES的组合物，以及检测细胞因子Eotaxin的组合物和检测细胞因子IP-10的组合物。The kit also includes a composition for detecting the cytokine RANTES, a composition for detecting the cytokine Eotaxin, and a composition for detecting the cytokine IP-10.
检测细胞因子RANTES的组合物包括RANTES的捕获抗体。Compositions for detecting the cytokine RANTES include capture antibodies to RANTES.
本发明技术方案实现的有益效果：The beneficial effect that technical solution of the present invention realizes:
通过检测本发明提供的细胞因子及其组合可为评价治疗方案在治疗早期对疗效进行预测提供参考，以利于及时调整治疗方案，提高结核病的治疗效果，减少无效药物的毒副作用，利于个性化医疗方案的实施。By detecting the cytokines and combinations thereof provided by the present invention, it can provide a reference for evaluating the treatment plan and predicting the curative effect in the early stage of treatment, so as to facilitate timely adjustment of the treatment plan, improve the treatment effect of tuberculosis, reduce the toxic and side effects of ineffective drugs, and facilitate personalized medicine implementation of the program.
附图说明Description of drawings
图1为细胞因子IFN-γ、IL-6、Eotaxin在各个疗程时间点的变化趋势图；Figure 1 is a trend chart of cytokines IFN-γ, IL-6, and Eotaxin at each time point of treatment;
图2为细胞因子IP-10和RANTES在各个疗程时间点的变化趋势图。Fig. 2 is the change trend diagram of cytokines IP-10 and RANTES at various time points of treatment courses.
具体实施方式detailed description
以下结合附图详细描述本发明的技术方案。本发明实施例仅用以说明本发明的技术方案而非限制，尽管参照较佳实施例对本发明进行了详细说明，本领域的普通技术人员应当理解，可以对发明的技术方案进行修改或者等同替换，而不脱离本发明技术方案的精神和范围，其均应涵盖在本发明的权利要求范围中。The technical solution of the present invention will be described in detail below in conjunction with the accompanying drawings. The embodiments of the present invention are only used to illustrate the technical solutions of the present invention without limitation. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solutions of the invention can be modified or equivalently replaced , without departing from the spirit and scope of the technical solution of the present invention, all of which shall be covered by the claims of the present invention.
本发明各个实施例获取数据的依据如下：The basis for obtaining data in each embodiment of the present invention is as follows:
肺结核组：Tuberculosis group:
实验样本入选83例于中心2014年3月至2014年10月间接受抗结核治疗的肺结核患者，男53例、女30例，收集其治疗期间EDTA抗凝血浆。要求入选者原则上年龄小于60周岁，排除其他慢性感染性疾病(如：肝炎等)及重大疾病(如：肿瘤和HIV等)，且之前没有抗结核治疗历史。The experimental samples were selected from 83 pulmonary tuberculosis patients who received anti-tuberculosis treatment in the center from March 2014 to October 2014, 53 males and 30 females, and EDTA anticoagulated plasma was collected during the treatment. Applicants are required to be younger than 60 years of age in principle, other chronic infectious diseases (such as: hepatitis, etc.) and major diseases (such as: cancer and HIV, etc.) are excluded, and there is no history of anti-tuberculosis treatment before.
健康体检组：Health checkup group:
入选29例四周内没有进行任何药物治疗的健康体检者。A total of 29 healthy individuals who did not receive any drug treatment within four weeks were selected.
样本采集与处理：Sample collection and processing:
EDTA抗凝管收集全血后，离心1000×g，15min，4℃。收集上层血浆，为了完全去除血小板和沉淀物，再次离心10000×g，10min，4℃。立即测定样本，或分装后-70℃保存。After collecting whole blood in EDTA anticoagulant tube, centrifuge at 1000×g, 15min, 4°C. Collect the upper layer of plasma, and centrifuge again at 10,000×g for 10 min at 4°C in order to completely remove platelets and precipitates. Measure samples immediately, or store at -70°C after aliquoting.
细胞因子实验：Cytokine experiment:
测定试剂盒为MAP Kit购自Merck Millipore(默克密理博)公司。本研究对肺结核患者治疗0、0.5、2、4和6个月的血浆和健康体检者的血浆进行检测，检测IFN-γ，IL-6、IP-10，eotaxin，RANTES五种细胞因子水平。细胞因子定量检测，严格按照MAP Kit试剂盒说明进行操作。The assay kit is MAP Kit was purchased from Merck Millipore (Merck Millipore). In this study, the plasma of tuberculosis patients treated for 0, 0.5, 2, 4 and 6 months and the plasma of healthy subjects were detected to detect the levels of five cytokines including IFN-γ, IL-6, IP-10, eotaxin and RANTES. Quantitative detection of cytokines, in strict accordance with MAP Kit instructions for operation.
统计方法：statistical methods:
实验数据用SPSS Statistics 17.0统计分析软件进行分析，各组数据用表示，利用Kolmogorov-Smirnov Test检验数据正态性；细胞因子浓度在治疗不同时间点及组间差异的比较采用重复测量资料的方差分析，P<0.05为差异有统计学意义，进一步的两两比较采用LSD法，治疗期的细胞因子水平与健康对照组间的差异比较采用Dunnett法。The experimental data was analyzed with SPSS Statistics 17.0 statistical analysis software, and each group of data was analyzed with Said that the Kolmogorov-Smirnov Test was used to test the normality of the data; the comparison of the cytokine concentration at different time points of treatment and the difference between the groups used the analysis of variance of the repeated measurement data, and P<0.05 indicated that the difference was statistically significant, and further pairwise comparisons The LSD method was used, and the difference between the cytokine levels in the treatment period and the healthy control group was compared with the Dunnett method.
实施例1Example 1
患者系列血浆中细胞因子在各治疗时期及各分组的水平统计结果：Statistical results of the levels of cytokines in the plasma of patients in each treatment period and each group:
IFN-γ、IL-6、Eotaxin、IP-10及RANTES五个细胞因子在83例患者系列血浆中的水平(平均数±标准差)统计，按照不同治疗时间分组，分别统计每种因子在不同治疗时间点之间数据的差异(参见表1、图1和图2)。IFN-γ, IL-6, Eotaxin, IP-10 and RANTES five cytokines in the plasma levels of 83 patients (mean ± standard deviation) were statistically grouped according to different treatment times, and each factor was counted separately in different Differences in data between treatment time points (see Table 1, Figure 1 and Figure 2).
表1 IFN-γ在系列血浆中的水平(平均数±标准差)Table 1 The levels of IFN-γ in serial plasma (mean ± standard deviation)
表1中，“*”代表与初诊(0个月)时血浆细胞因子浓度相比较P<0.05；“#”代表与治疗6个月血浆细胞因子浓度相比较P<0.05。In Table 1, "*" represents P<0.05 compared with the plasma cytokine concentration at the first diagnosis (0 month); "#" represents P<0.05 compared with the plasma cytokine concentration at 6 months of treatment.
实施例2Example 2
各细胞因子水平在肺结核患者治疗时期与健康体检者之间的差异统计Statistical difference of each cytokine level between tuberculosis patients during treatment and healthy subjects
以各治疗时期的血浆细胞因子水平为一个组，统计其与健康人之间的差异是否有统计学意义，结果显示肺结核患者在整个治疗期间的血浆中，Eotaxin、IP-10及RANTES的水平均与健康体检者存在显著性差异(P<0.05)(表2)。由图2B提示，RANTES在治疗两个月一直到治疗6个月的水平已经下降到健康人水平。表3统计了Eotaxin、IP-10及RANTES的水平在各个时间点与健康体检者的差异，Eotaxin的水平在治疗各个治疗时间点始终高于健康体检者；IP-10的水平在治疗2周和2个月时显著高于健康体检者，随着治疗的进行在4～6个月时水平虽然高于健康体检者，但差异没有统计学意义；RANTES的水平在治疗2周时显著高于健康体检者，在治疗2个月之后其水平已趋于健康体检者水平，差异无统计学意义。Taking the plasma cytokine levels in each treatment period as a group, it was counted whether the difference between them and healthy people was statistically significant. The results showed that the levels of Eotaxin, IP-10 and RANTES in the plasma of tuberculosis patients during the entire treatment period were average There was a significant difference (P<0.05) with healthy subjects (Table 2). As shown in Figure 2B, the level of RANTES has dropped to the level of healthy people after two months of treatment until six months of treatment. Table 3 counts the differences between the levels of Eotaxin, IP-10 and RANTES at each time point and healthy persons, and the level of Eotaxin is always higher than that of healthy persons at each time point of treatment; At 2 months, it was significantly higher than that of the healthy subjects. As the treatment progressed, the level was higher than that of the healthy subjects at 4 to 6 months, but the difference was not statistically significant; the level of RANTES was significantly higher than that of the healthy subjects at 2 weeks of treatment. After 2 months of treatment, the level of those who underwent physical examination has tended to the level of those who received healthy physical examination, and the difference was not statistically significant.
表2 各细胞因子水平在患者治疗时期与健康体检者之间的差异统计Table 2 Statistical differences of each cytokine level between the treatment period of the patients and the healthy subjects
表3 Eotaxin、IP-10及RANTES在患者治疗各个时间点分别与健康体检者之间的差异统计Table 3 Statistical differences between Eotaxin, IP-10 and RANTES at each time point of treatment between patients and healthy persons
表3中，“*”代表与健康体检者血浆细胞因子浓度相比较P<0.05。In Table 3, "*" represents P<0.05 compared with the plasma cytokine concentration of healthy subjects.
实施例3Example 3
5种细胞因子在治疗前与满疗程治疗6个月后的浓度变化趋势Concentration trends of 5 cytokines before treatment and after 6 months of full course of treatment
83例肺结核患者治疗前与满疗程治疗6个月后的血浆细胞因子变化趋势如表4所示，该表总结了治疗前后各细胞因子上升、下降以及不变的患者例数，及其在83例患者中所占比例。结果显示：Eotaxin的水平呈上升趋势的较多，其余四个因子的水平均以下降为主，其中有95％的患者血浆RANTES水平呈下降趋势。The change trend of plasma cytokines in 83 patients with pulmonary tuberculosis before treatment and after 6 months of full course of treatment is shown in Table 4. proportion of patients. The results showed that the level of Eotaxin showed an upward trend, and the levels of the other four factors mainly decreased, and the plasma RANTES level of 95% of the patients showed a downward trend.
表4 5种细胞因子在治疗前后的浓度变化趋势Table 4 Concentration trend of 5 cytokines before and after treatment
由以上结果可见：It can be seen from the above results:
1)随着治疗的进行，Eotaxin、IP-10及RANTES的水平在患者血浆中的水平发生了显著性的改变(P<0.001)，IP-10的水平在患者总体经过6个月治疗后，显著低于初诊及治疗初期；RANTES在总体及各个分组的治疗后各个时间节点均与初诊水平存在显著性差异，且治疗2个月与治疗6个月后水平的差异不具有统计学意义，提示RANTES在治疗2周至2个月期间的变化趋势可以用于评估疾病疗效。1) With the progress of treatment, the levels of Eotaxin, IP-10 and RANTES in the plasma levels of patients changed significantly (P<0.001), and the level of IP-10 in patients after 6 months of treatment overall, Significantly lower than the first diagnosis and initial treatment; RANTES in the overall and each time point after treatment in each group has a significant difference from the first diagnosis level, and the difference between the level after 2 months of treatment and the level after 6 months of treatment is not statistically significant, suggesting that The change trend of RANTES during 2 weeks to 2 months of treatment can be used to evaluate the efficacy of the disease.
2)患者血浆中RANTES的水平在治疗2个月之后已经达到健康人水平，提示RANTES的治疗早期水平可能更适用于疗效预测。2) The level of RANTES in the patient's plasma has reached the level of healthy people after 2 months of treatment, suggesting that the level of RANTES in the early stage of treatment may be more suitable for efficacy prediction.
3)5种细胞因子在治疗前与满疗程治疗6个月后，83例肺结核患者血浆内Eotaxin的水平呈上升趋势的较多，其余四因子的水平均以下降为主，其中RANTES的下降比例最高为95％。3) The levels of Eotaxin in the plasma of 83 patients with pulmonary tuberculosis tended to rise more before treatment and 6 months after the full course of treatment for the five cytokines, while the levels of the other four factors mainly decreased, among which the proportion of RANTES decreased Up to 95%.
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610918234.3ACN106568972A (en) | 2016-10-21 | 2016-10-21 | A cytokine used for evaluating tuberculosis treatment and a kit thereof |
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610918234.3ACN106568972A (en) | 2016-10-21 | 2016-10-21 | A cytokine used for evaluating tuberculosis treatment and a kit thereof |
| Publication Number | Publication Date |
|---|---|
| CN106568972Atrue CN106568972A (en) | 2017-04-19 |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610918234.3APendingCN106568972A (en) | 2016-10-21 | 2016-10-21 | A cytokine used for evaluating tuberculosis treatment and a kit thereof |
| Country | Link |
|---|---|
| CN (1) | CN106568972A (en) |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113406334A (en)* | 2021-06-02 | 2021-09-17 | 浙江省人民医院 | DLBCL (digital Living chromosome binding protein) related biomarker composition, application thereof and DLBCL prognosis effect prediction model |
| CN113607955A (en)* | 2020-09-16 | 2021-11-05 | 广州中医药大学顺德医院(佛山市顺德区中医院) | Novel coronavirus pneumonia staging and curative effect evaluation cytokine marker and application thereof |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013175459A2 (en)* | 2012-05-25 | 2013-11-28 | Stellenbosch University | Method for diagnosing tuberculosis disease |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013175459A2 (en)* | 2012-05-25 | 2013-11-28 | Stellenbosch University | Method for diagnosing tuberculosis disease |
| Title |
|---|
| J.F. DJOBA SIAWAYA ET AL: "Differential cytokine secretion and early treatment response in patients with pulmonary tuberculosis", 《CLINICAL AND EXPERIMENTAL IMMUNOLOGY》* |
| MENG RUI LEE ET AL: "Plasma Biomarkers Can Predict Treatment Response in Tuberculosis Patients: A Prospective Observational Study", 《MEDICINE》* |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113607955A (en)* | 2020-09-16 | 2021-11-05 | 广州中医药大学顺德医院(佛山市顺德区中医院) | Novel coronavirus pneumonia staging and curative effect evaluation cytokine marker and application thereof |
| CN113406334A (en)* | 2021-06-02 | 2021-09-17 | 浙江省人民医院 | DLBCL (digital Living chromosome binding protein) related biomarker composition, application thereof and DLBCL prognosis effect prediction model |
| Publication | Publication Date | Title |
|---|---|---|
| Ang et al. | Aqueous cytokine and chemokine analysis in uveitis associated with tuberculosis | |
| CN109991417B (en) | Immune marker for tuberculosis and application | |
| CN106947835A (en) | The authentication method of ebv infection lymphocyte subgroup and its application | |
| Ashenafi et al. | Inflammatory immune profiles associated with disease severity in pulmonary tuberculosis patients with moderate to severe clinical TB or anemia | |
| Xu et al. | Dynamic Changes of Th1 Cytokines and the Clinical Significance of the IFN‐γ/TNF‐α Ratio in Acute Brucellosis | |
| CA2924405C (en) | Biomarkers for tuberculosis | |
| Çelik et al. | The CXCL9/10/11-CXCR3 axis as a predictor of COVID-19 progression: a prospective, case-control study | |
| CN106568972A (en) | A cytokine used for evaluating tuberculosis treatment and a kit thereof | |
| Zeng et al. | Intravenous cyclophosphamide therapy for Anti-IFN-γ Autoantibody-Associated Talaromyces marneffei infection | |
| AU2012236137A1 (en) | Use of cytokine levels in intravenous immunoglobulin treatment of Alzheimer's disease | |
| CN113552347A (en) | Application of reagent for detecting follicular regulatory T cells in preparation of diagnostic reagent for prognosis of immunotherapy of allergic rhinitis | |
| CN114675036A (en) | A marker for diagnosing T-SPOT negative tuberculosis and its application | |
| Zeng et al. | Primary immunodeficiency in south China: clinical features and a genetic subanalysis of 138 children | |
| CN116609530A (en) | Marker for diagnosing tuberculosis infection and application thereof | |
| CN106568970A (en) | IP10 and interleukin combined cytokine for diagnosis of tuberculosis and kit thereof | |
| CN106546746A (en) | For the IP10 cytokines and its test kit of diagnosis of tuberculosis | |
| CN106568971A (en) | IP10 and Eotaxin combined cell factor for diagnosing tuberculosis and kit thereof | |
| CN106556697A (en) | IP10 and the interferon associational cells factor and its kit for diagnosis of tuberculosis | |
| JP6206953B2 (en) | Method for testing the likelihood of developing adult T-cell leukemia | |
| CN112858688A (en) | Application of SLAMF 7-expressed CD4+ T cells in preparation of tuberculosis diagnosis or treatment reagent | |
| Tamene et al. | Protein Expression of TLR2, TLR4, and TLR9 on Monocytes in TB, HIV, and TB/HIV | |
| OSENI et al. | Rheumatoid arthritis: peripheral blood cells and plasma protein characteristics in geriatric patients | |
| He et al. | Peripheral blood smears distinguish infective fever after CAR-T therapy | |
| KR102395882B1 (en) | Biomarkers for simultaneous diagnosis of active tuberculosis and latent tuberculosis infection | |
| CN115877017B (en) | Products and systems for predicting immune reconstitution in HIV/AIDS patients |
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | Application publication date:20170419 | |
| RJ01 | Rejection of invention patent application after publication |